Facemask Testing

One of the main factors influencing the amount of inhaled drug available to the patient is the interface between the facemask and the patient. Investigating and defining the effect of a facemask to the product’s DDU and APSD is important for the product development.

Please select an option:

Please select an option:

Related Services

Related News & Resources

Copley Scientific joins the Industries Forum of the Taskforce for Lung Health

22nd June 2021

Find out more

Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio

1st March 2021

Find out more

New e-Training service from Copley for pharmaceutical testing

29th January 2021

Find out more

Copley Scientific releases new accessories for testing nebulisers with facemasks

31st May 2018

Find out more

Copley Scientific previews new apparatus for metered dose inhaler testing at DDL 25

11th November 2014

Find out more

Putting Inhalers to the Test

View download

A short Q&A with our CEO, Mark Copley, On Inhaled Product Testing

View download

Optimizing the Application of In Vitro Test Methods for the Demonstration of Bioequivalence in Orally Inhaled Products

View download

Demonstrating Bioequivalence of Orally Inhaled Products

View download

Optimising the Application of In Vitro Test Methods for the Demonstration of BE in OIPs

View download

Characterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing

View download